No Data
No Data
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long
Top Picks for 2025 in Healthcare, Consumer, Tech, Industrials, Energy and More
Zevra Therapeutics to Be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
Zevra Therapeutics Restructures to Focus on Rare Diseases
Zevra Therapeutics Announces Departure of CDO Christal Mickle, CSO Sven Guenther
Express News | Zevra Therapeutics Inc - Christal M.m. Mickle, Chief Development Officer, and Sven Guenther, Ph.d., Chief Scientific Officer, to Depart Co